NewsRoom Articles - Page 69 of 154 - PsychedelicNewsWire (PNW)

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

MondayFeb 14, 2022 12:32 pm

What You Should Consider Before Investing in Psychedelics Space

The psychedelics industry is projected to grow at a compound annual growth rate of 14.5% in the short term, hitting $6.3 billion by 2026. Psychedelics present an attractive investment opportunity for any investors seeking to diversify their portfolio. However, like most major decisions in life, investing hard-earned money should be done with a lot of forethought and caution, especially when dealing with products that have a lot of room for growth, such as psychedelics. To help stake a profitable position in the burgeoning psychedelics space, potential investors will need to understand that experts’ expectations of psychedelics blowing up in the…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

FridayFeb 11, 2022 2:03 pm

Seattle Doctor Petitions DEA to Reschedule Psilocybin

Last week, Seattle doctor Sunil Aggarwal filed a petition with the Drug Enforcement Agency (“DEA”) challenging its Schedule I classification of psilocybin, which is the primary psychoactive component of hallucinogenic mushrooms. The federal petition filed by the doctor, who specializes in end-of-life care, requests that the DEA reschedule psilocybin as a Schedule II drug given the potential it has shown in relieving symptoms of various ailments including depression and anxiety caused by a terminal disease diagnosis. The petition also highlights how decades of research have shown that psilocybin has a low potential for abuse in comparison with other substances under…

FridayFeb 11, 2022 9:15 am

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28 Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystem The laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue supporting the cannabis industry with the latest technology and services as the cannabis market and cannabis extraction spaces mature Delic Holdings (CSE: DELC) (OTCQB: DELCF) recently announced that Dr. Markus Roggen – the President and Chief Science Officer of Delic Labs, a federally licensed cannabis…

ThursdayFeb 10, 2022 1:24 pm

Activists in Michigan File Psychedelic Legalization Voter Initiative

Activists in the state of Michigan have filed a ballot measure that will legalize the possession, cultivation and sharing of psychedelic substances as well as establish a system for the spiritual and therapeutic use of psychedelics, if approved. The Students for Sensible Drug Policy, a youth-led organization, and the Michigan Chapter of Decriminalize Nature worked together on this effort. The state’s ballot initiative would legalize various entheogenic substances, including DMT, peyote, mescaline, ibogaine, psilocin and psilocybin, for individuals aged 18 and above. During a recent interview, codirector of Decriminalize Nature Michigan Myc Williams stated that the two groups were excited…

WednesdayFeb 09, 2022 1:48 pm

Study Uses Linguistic Analysis to Find Differences in Effects of Psychedelic Experiences

A new study looked into the various types of subjective experiences produced by five types of psychedelic drugs. Using computer algorithms, the researchers conducted an analysis of thousands of reports on the effects of psychedelic substances that were anonymously published. Research has shown that psychedelic substances, including psilocybin and MDMA, possess the potential to treat psychiatric conditions such as PTSD and depression. While various studies have shown that these drugs cause changes in an individual’s consciousness and perception, minimal research has been conducted quantifying the experiences linked to the consumption of these drugs. Adrian Hase, a postdoctoral researcher at the…

TuesdayFeb 08, 2022 3:49 pm

MAPS Is Developing Training Program on How to Deal with Bad Psychedelic Trips

Psychedelics sometimes cause bad trips by creating horrible scenarios for some individuals. Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (“MAPS”), recently talked about difficult trips and how people could be guided through these experiences. During a recent interview, Doblin, a psychonaut and veteran psychedelic researcher, was asked whether MAPS would start a psychonaut training program based partly on principles of psychedelic harm reduction. Doblin revealed that the program, which was briefly referenced on the MAP’s website, was still being developed but would launch in various parts of North America where psychedelic substances had been decriminalized. He…

TuesdayFeb 08, 2022 12:05 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans

Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a psychoactive-assisted psychotherapy PTSD treatment program for veterans Combat Stress will also be one of several sites for the company’s upcoming clinical trials set to launch later in the year Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) plans to launch its seamless phase 2/3 smoking cessation…

MondayFeb 07, 2022 2:09 pm

New Study Finds Weak Link Between Symptoms of Psychosis, Psychedelic Use

A new study has found that individuals who consume psychedelic substances are more likely to report symptoms associated with psychosis, which can be explained by the use of other psychoactive drugs and the presence of other mental health disorders. Psychedelics are drugs that can alter an individual’s cognition, mood and perception. This class of drugs produces hallucinogenic effects when used. Common psychedelics include psilocybin and LSD. Scientific studies conducted in the recent past have found evidence showing the possible therapeutic effects of these substances. However, few studies have looked into the potential harmful psychological effects associated with the use of…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000